Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
As non-UK medical device manufacturers plan for the UK's evolving regulatory framework, what is a comprehensive methodology for selecting a UK Responsible Person (UKRP) that extends beyond the minimum...
For non-UK medical device manufacturers planning to enter or remain on the Great Britain market, appointing a UK Responsible Person (UKRP) is a mandatory step. While budgeting for this service is cruc...
When a non-EU cosmetics brand prepares for compliance with evolving EU regulations, what practical criteria should be used to evaluate and select a suitable Responsible Person (RP)? Beyond simply havi...
For non-EU medical device manufacturers, selecting an EU Authorised Representative (AR) under the MDR or IVDR is a critical compliance decision with significant legal implications. Beyond simply appoi...
When a manufacturer modifies a cleared Software as a Medical Device (SaMD) that incorporates a machine learning (ML) algorithm, how is the determination made whether the change requires a new 510(k) s...
For a medical device or Software as a Medical Device (SaMD) manufacturer that processes the personal health data of EU residents, how should the organization approach budgeting for a GDPR Article 27 r...
For non-EU medical device manufacturers, selecting an EU Authorized Representative (AR) is a critical compliance step under the EU Medical Device Regulation (MDR). This role extends far beyond a simpl...
Beyond the initial annual retainer fee, how can medical device manufacturers accurately forecast the total cost of partnership with an EU Authorized Representative (AR) under the stringent requirement...
For foreign manufacturers of generic drugs, understanding the costs associated with entering the U.S. market is a critical planning step. A common point of confusion is the distinction between officia...
With the FDA’s Quality Management System Regulation (QMSR) final rule taking effect on February 2, 2026, foreign medical device establishments must re-evaluate the capabilities of their U.S. Agent. Th...
When preparing to place a cosmetic product on the European Union market, manufacturers outside the EU must appoint a Responsible Person (RP). While specific fees vary, understanding the factors that d...
When evaluating the cost structure for an EU Responsible Person (RP) to ensure compliance with cosmetic regulations, what are the key service components and pricing models that a non-EU brand must ana...
When preparing a premarket submission for a connected medical device, such as a continuous glucose monitoring system or a software-based diagnostic tool, how should a sponsor approach cybersecurity do...
For non-EU based medical device and Software as a Medical Device (SaMD) manufacturers that process personal data of individuals in the European Union, what are the core functions and potential liabili...
When a non-EU manufacturer seeks to place a medical device on the European market, they must appoint an EU Authorized Representative (AR). While the fee structures for AR services can vary significant...
What key factors and due diligence steps should a non-EU medical device manufacturer implement when selecting an EU Authorized Representative (AR) under the Medical Device Regulation (EU) 2017/745? Be...
As foreign medical device establishments prepare for the FDA's Quality Management System Regulation (QMSR) to take effect on February 2, 2026, what constitutes a comprehensive strategy for selecting o...
For foreign medical device manufacturers preparing for the FDA's Quality Management System Regulation (QMSR) effective date of February 2, 2026, how should the selection of an FDA U.S. Agent be approa...
When evaluating external "Person Responsible for Regulatory Compliance (PRRC) as a Service" providers under the EU Medical Device Regulation (MDR), how can a startup or small manufacturer move beyond ...
When planning for 2026, how can a medical device manufacturer accurately forecast the cost of engaging an external 'Person Responsible for Regulatory Compliance' (PRRC) as a Service under the EU MDR, ...